SCHEMBL4166464

SCHEMBL4166464

CCOC(=O)CCC1CCc2cccnc2C1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 5/20 0.45
HTR1A P08908 4/20 0.45
DRD2 P14416 4/20 0.45
HRH1 P35367 5/20 0.42
NOTUM Q6P988 1/20 0.40
LMNA P02545 3/20 0.38
MAPT P10636 2/20 0.38
CYP2C19 P33261 2/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
CACNA1F O60840 1/20 0.38
NR1I2 O75469 1/20 0.38
GMNN O75496 1/20 0.38
USP2 O75604 1/20 0.38
ABCB11 O95342 1/20 0.38
TP53 P04637 1/20 0.38
CHRM2 P08172 1/20 0.38
ABCB1 P08183 1/20 0.38
CYP3A4 P08684 1/20 0.38
ADORA3 P0DMS8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4170864 0.93 HRH1 (0.41) HTR2AHTR1ADRD2HRH1NOTUM
SCHEMBL13875278 0.81 DRD2 (0.49) HTR2AHTR1ADRD2MAPTMEN1
SCHEMBL8534761 0.81 ALDH1A1 (0.52) HTR1ANOTUMLMNAMAPTCYP2C19
SCHEMBL2877908 0.81 HRH1 (0.45) HTR2AHRH1LMNAMAPTCYP2C19
SCHEMBL924605 0.78 HTR1A (0.43) HTR2AHTR1ADRD2HRH1SLC6A15
SCHEMBL19838569 0.74 CYP11B1 (0.44) HRH1LMNACYP2C19MEN1TP53
SCHEMBL2880939 0.74 OPRL1 (0.50) HTR2AHRH1LMNAMAPTCYP2C19
SCHEMBL17211829 0.74 CYP24A1 (0.44) LMNAMAPTMEN1KMT2AALDH1A1
SCHEMBL2882382 0.73 HRH1 (0.43) HTR2AHRH1LMNAMAPTCYP2C19
SCHEMBL14062161 0.73 CYP26A1 (0.55) CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368146-A1 Morpholine-Containing & Piperazine-Containing CXCR4 Modulators and Uses Related Thereto UNIV EMORY (US) 2024-11-07 US disclosed
EP-4373485-A1 CXCR4 MODULATORS AND USES RELATED THERETO Emory University (US) 2024-05-29 EP disclosed
WO-2023003862-A1 CXCR4 MODULATORS AND USES RELATED THERETO EMORY UNIVERSITY (US) 2023-01-26 WO disclosed
US-20090093454-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2009-04-09 US disclosed
US-20090093454-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2009-04-09 US disclosed
US-20090093454-A1 Chemical Compounds SMITHKLINE BEECHAM CORPORATION 2009-04-09 US disclosed
EP-1853604-A2 CHEMICAL COMPOUNDS SmithKline Beecham Corporation (US) 2007-11-14 EP disclosed
WO-2006096444-A2 CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-09-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368146-A1 Morpholine-Containing & Piperazine-Containing CXCR4 Modulators and Uses Related Thereto CXCR4, CXCL12, MYD88 HTR2A 674/4885HTR1A 1055/4885DRD2 1838/4885
US-20090093454-A1 Chemical Compounds SLC10A1, CYP11B2, CYP4F3 HTR2A 1676/4885HTR1A 1175/4885DRD2 2428/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.